<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940522</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-HPC-PK-010</org_study_id>
    <nct_id>NCT02940522</nct_id>
  </id_info>
  <brief_title>Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that a single dose of Makena® delivered SQ via auto-injector has comparable
      bioavailability to a single IM injection of Makena®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf] for the Primary PK Population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of the maximum plasma concentration (Cmax) for the Primary PK Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tmax</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of PK parameter Tmax for the Primary PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of AUC (0-168)</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of PK Parameter AUC (0-168) for the Primary PK Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of t1/2</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of PK parameter t1/2 for the Primary PK Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Elimination Rate Constant</measure>
    <time_frame>9 weeks</time_frame>
    <description>Comparison of the elimination rate constant for the Primary PK Population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SQ) injection using an autoinjector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injection (IM) using syringe and needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Makena SQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Makena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Naturally or surgically postmenopausal women, with or without an intact uterus, aged 50
        to 75 years of age, inclusive. FSH levels greater than 40 mIU/mL

        Exclusion Criteria:

          1. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).

          2. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any
             of the constituents of the study medications, or history of any drug hypersensitivity
             or intolerance

          3. Poorly controlled diabetes.

          4. History or current evidence of deep vein thrombosis, pulmonary embolism or arterial
             thromboembolic disease (e.g., stroke, myocardial infarction).

          5. Known, suspected, or current history of carcinoma of the breast.

          6. Subjects with a past history of breast cancer on aromatase inhibitors or selective
             estrogen receptor modulators.

          7. Known, suspected, or current history of hormone dependent tumor within the last 5
             years.

          8. Any current or recent (within previous 12 months) genital bleeding of unknown
             etiology.

          9. Receipt of any investigational drug within 30 days.

         10. Receipt of any prescription or OTC medications that are known to alter CYP3A4 or
             CYP3A5 levels (e.g., carbamazepine, St. John's Wort, ketoconazole, rifampin,
             ritonavir, alprazolam, azithromycin, loratadine, etc.) within 14.

         11. Any estrogen, progestin, or selective estrogen receptor modulator (SERM) treatment
             within specified time windows before the study start, ranging from 2 to 6 months.

         12. High blood pressure at the screening evaluation, defined as systolic blood pressure &gt;
             150 mm Hg or diastolic blood pressure &gt; 90 mm Hg.

         13. History of excessive alcohol consumption (on average more than 14 units of
             alcohol/week) during the past 12 months.

         14. Use of tobacco products within 30 days of the start of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Krop, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AMAG Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <results_first_submitted>April 24, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2018</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A</title>
          <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
        <group group_id="P2">
          <title>Treatment B</title>
          <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment A</title>
          <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
        <group group_id="B2">
          <title>Treatment B</title>
          <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="6.16"/>
                    <measurement group_id="B2" value="57.0" spread="5.68"/>
                    <measurement group_id="B3" value="58.4" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]</title>
        <description>Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf] for the Primary PK Population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf]</title>
          <description>Comparison of areas under the curve (AUC) to the last time with a concentration ≥ LLOQ [AUC0-t] and to infinity [AUCinf] for the Primary PK Population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>hr x ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,313" spread="23.5"/>
                    <measurement group_id="O2" value="2,098" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(inf)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,469" spread="22.8"/>
                    <measurement group_id="O2" value="2,175" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Maximum Plasma Concentration (Cmax)</title>
        <description>Comparison of the maximum plasma concentration (Cmax) for the Primary PK Population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Maximum Plasma Concentration (Cmax)</title>
          <description>Comparison of the maximum plasma concentration (Cmax) for the Primary PK Population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="71.9"/>
                    <measurement group_id="O2" value="6.91" spread="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability data</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Tmax</title>
        <description>Comparison of PK parameter Tmax for the Primary PK population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Tmax</title>
          <description>Comparison of PK parameter Tmax for the Primary PK population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" lower_limit="18" upper_limit="342"/>
                    <measurement group_id="O2" value="49.7" lower_limit="2" upper_limit="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability data</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of AUC (0-168)</title>
        <description>Comparison of PK Parameter AUC (0-168) for the Primary PK Population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of AUC (0-168)</title>
          <description>Comparison of PK Parameter AUC (0-168) for the Primary PK Population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>hr x ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813" spread="41.5"/>
                    <measurement group_id="O2" value="790" spread="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability data</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of t1/2</title>
        <description>Comparison of PK parameter t1/2 for the Primary PK Population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of t1/2</title>
          <description>Comparison of PK parameter t1/2 for the Primary PK Population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="29.1"/>
                    <measurement group_id="O2" value="185" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability data</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Elimination Rate Constant</title>
        <description>Comparison of the elimination rate constant for the Primary PK Population</description>
        <time_frame>9 weeks</time_frame>
        <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Elimination Rate Constant</title>
          <description>Comparison of the elimination rate constant for the Primary PK Population</description>
          <population>The Primary PK Population consisted of 45 subjects each for both treatments for whom whole blood was analyzed. Subjects were excluded from Treatment A and Treatment B due to insufficient number of samples for planned analyses.</population>
          <units>1/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0033" spread="29.1"/>
                    <measurement group_id="O2" value="0.0038" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of bioavailability data</non_inferiority_desc>
            <other_analysis_desc>The PK parameters were compared between treatments using an analysis of variance statistical model with treatment as the fixed effect, using the natural logarithms of the data. As the objective was to assess whether comparable exposure could be obtained using the higher SQ dose, the data were not normalized for dose before the statistical analysis.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Subcutaneous (SQ) injection using an autoinjector
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Intramuscular injection (IM) using syringe and needle
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="59"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Injection site pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>AMAG Pharmaceuticals, Inc.</organization>
      <phone>1-877-411-2510</phone>
      <email>amag@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

